Skip to Content
Merck
CN
  • Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice.

Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice.

Hepatology (Baltimore, Md.) (2014-05-16)
Pedro Elias Marques, André Gustavo Oliveira, Rafaela Vaz Pereira, Bruna Araújo David, Lindisley Ferreira Gomides, Adriana Machado Saraiva, Daniele Araújo Pires, Júlia Tosta Novaes, Daniel O Patricio, Daniel Cisalpino, Zélia Menezes-Garcia, W Matthew Leevy, Sarah Ellen Chapman, GermánArturo Mahecha, Rafael Elias Marques, Rodrigo Guabiraba, Vicente Paulo Martins, Danielle Gloria Souza, Daniel Santos Mansur, Mauro Martins Teixeira, M Fatima Leite, Gustavo Batista Menezes
ABSTRACT

Drug-induced liver injury (DILI) is an important cause of acute liver failure, with limited therapeutic options. During DILI, oncotic necrosis with concomitant release and recognition of intracellular content amplifies liver inflammation and injury. Among these molecules, self-DNA has been widely shown to trigger inflammatory and autoimmune diseases; however, whether DNA released from damaged hepatocytes accumulates into necrotic liver and the impact of its recognition by the immune system remains elusive. Here we show that treatment with two different hepatotoxic compounds (acetaminophen and thioacetamide) caused DNA release into the hepatocyte cytoplasm, which occurred in parallel with cell death in vitro. Administration of these compounds in vivo caused massive DNA deposition within liver necrotic areas, together with an intravascular DNA coating. Using confocal intravital microscopy, we revealed that liver injury due to acetaminophen overdose led to a directional migration of neutrophils to DNA-rich areas, where they exhibit an active patrolling behavior. DNA removal by intravenous DNASE1 injection or ablation of Toll-like receptor 9 (TLR9)-mediated sensing significantly reduced systemic inflammation, liver neutrophil recruitment, and hepatotoxicity. Analysis of liver leukocytes by flow cytometry revealed that emigrated neutrophils up-regulated TLR9 expression during acetaminophen-mediated necrosis, and these cells sensed and reacted to extracellular DNA by activating the TLR9/NF-κB pathway. Likewise, adoptive transfer of wild-type neutrophils to TLR9(-/-) mice reversed the hepatoprotective phenotype otherwise observed in TLR9 absence. Hepatic DNA accumulation is a novel feature of DILI pathogenesis. Blockage of DNA recognition by the innate immune system may constitute a promising therapeutic venue.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥97.5% (HPLC)
Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
Propidium iodide, ≥94% (HPLC)
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, 98%
Paracetamol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Rhodamine 6G, Dye content ~95 %
Supelco
Rhodamine 6G, analytical standard
Sigma-Aldrich
Rhodamine 6G, suitable for fluorescence, BioReagent
Isoflurane, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Rhodamine 6G, Dye content 99 %
Supelco
Acetaminophen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Propidium iodide solution
Supelco
Acetaminophen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Acetaminophen, BioXtra, ≥99.0%
USP
Acetaminophen, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Acetaminophen, analytical standard
Sigma-Aldrich
Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
Thioacetamide, reagent grade, 98%
Sigma-Aldrich
Thioacetamide, ACS reagent, ≥99.0%
Sigma-Aldrich
Thioacetamide, Vetec, reagent grade, 98%